Phase II Study of Stereotactic Radiosurgery for Brain Metastases in Adults with Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating stereotactic radiosurgery SRS as a treatment for people newly diagnosed with brain metastases from small cell lung cancer SCLC. This Phase II study aims to assess the effectiveness of SRS in this condition. Participants may be newly diagnosed with brain metastases at initial staging or may develop brain metastases while on therapy or surveillance for systemic disease. The study is sponsored by Memorial Sloan Kettering Cancer Center and focuses on treatment outcomes. Participants will receive SRS following standard procedures at MSK. This includes a CT simulation and contrast-enhanced MRI for precise treatment planning. The visible tumor on imaging defines the target area, which is expanded slightly to create the treatment volume. Radiation doses will range from 16Gy to 30Gy, delivered in 1 to 5 sessions based on the treating radiation oncologists discretion. Patients with multiple brain lesions may receive different doses for each lesion. Concurrent treatment of other body sites is allowed. Additionally, lumbar punctures will be performed for cerebrospinal fluid collection at enrollment and optionally at 3 months and disease progression for cytology evaluation. During the study, participants will undergo imaging and lumbar punctures as described, with assessments including overall survival measured at 6 months. Participants must have adequate performance status and be able to consent. Safety and treatment effects will be closely monitored through imaging and clinical evaluations. The study enrollment and treatment period extends until June 2027, with follow-ups as required. This setup allows researchers to gather data on the impact of SRS on survival and disease control in this patient group.

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain